Polymorphisms of estrogen-metabolizing genes and risk of hepatocellular carcinoma in Taiwan females

Cancer Letters

Volumn 212, Issue 2, 2004, Pages 195-201

  Yin, Pen Hui ^a   Lee, Hsin Chen ^a   Chau, Gar Yang ^a,b   Liu, Tsung Yun ^a,b   Liu, Hsiu Chih ^a,b   Lui, Wing Yiu ^a,b   Chi, Chin Wen ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

catechol O methyltransferase; COMT; CYP; CYP17; CYP1A1; cytochrome P450; HCC; hepatocellular carcinoma; Hepatocellular carcinoma; Polymorphism; restriction fragment length polymorphism; RFLP

Indexed keywords

CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 17; CYTOCHROME P450 1A1; ESTROGEN;

ARTICLE; BIOGENESIS; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME ACTIVITY; ENZYME INDUCTION; ESTROGEN METABOLISM; FEMALE; GENOTYPE; HETEROZYGOSITY; HIGH RISK POPULATION; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; HYDROXYLATION; LIVER CELL CARCINOMA; LOGISTIC REGRESSION ANALYSIS; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN VARIANT; SEX DIFFERENCE; TAIWAN;

CARCINOMA, HEPATOCELLULAR; CATECHOL O-METHYLTRANSFERASE; CYTOCHROME P-450 CYP1A1; DNA; ESTROGENS; FEMALE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RECEPTORS, ESTROGEN; RISK; STEROID 17-ALPHA-HYDROXYLASE; TAIWAN;

EID: 3242887068     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2004.04.032     Document Type: Article

References (36)

1. C.J. Chen, M.W. Yu and Y.F. Liaw Epidemiological characteristics and risk factors of hepatocellular carcinoma J. Gastroenterol. Hepatol. 12 1997 S294 S308
2. N. Nagasue, G. Galizia, H. Yukaya, H. Kohno, Y.C. Chang, and T. Hayashi Better survival in women than in men after radical resection of hepatocellular carcinoma Hepato-Gastroenterology 36 1989 379 383
3. S.C. Jwo, J.H. Chiu, G.Y. Chau, C.C. Loong and W.Y. Lui Risk factors linked to tumor recurrence of human hepatocellular carcinoma after hepatic resection Hepatology 16 1992 1367 1371
4. H.B. El-Serag, A.C. Mason and C. Key Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States Hepatology 33 2001 62 65
5. J.D. Yager and R. Yager Oral contraceptive steroids as promoters of hepatocarcinogenesis in female Sprague-Dawley rats Cancer Res. 40 1980 3680 3685
6. J.D. Yager Endogenous estrogens as carcinogens through metabolic activation J. Natl. Cancer Inst. Monogr. 27 2000 67 73
7. J.E. Coe, K.I. Ishak and M.J. Ross Estrogen induction of hepatocellular carcinoma in Armenian Hamsters Hepatology 11 1990 570 577
8. Y. Hiraku, N. Yamashita, M. Nishiguchi and S. Kawanishi Catechol estrogens induce oxidative DNA damage and estadiol enhances cell proliferation Int. J. Cancer 92 2001 333 337
9. E. Cavalieri, K. Frenkel, J.G. Liehr, E. Rogan and D. Roy Eetrogens as endogenous genotoxic agents-DNA adducts and mutations J. Natl. Cancer Inst. Monogr. 27 2000 75 93
10. R.R. Newbold and J.G. Liehr Induction of uterine adenocarcinoma in CD-1 mice by catechol estrogens Cancer Res. 60 2000 235 237
11. J.D. Yager and J.G. Liehr Molecular mechanisms of estrogen carcinogenesis Annu. Rev. Pharmacol. Toxicol. 36 1996 203 232
12. A.H. Carey, D. Waterworth, K. Patel, D. White, J. Little, and P. Novelli Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17 Hum. Mol. Genet. 3 1994 1873 1876
13. H.S. Feigelson, L.S. Shames, M.C. Pike, G.A. Coetzee, F.Z. Stanczyk and B.E. Henderson Cytochrome P450c17alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations Cancer Res. 58 1998 585 587
14. Y. Miyoshi and S. Noguchi Polymorphisms of estrogen synthesizing and metabolizing genes and breast cancer risk in Japanese women Biomed. Pharmacothe. 57 2003 471 481
15. D.D. Petersen, C.E. Mckinney, K. Ikeya, H.H. Smith, A.E. Bale, and O.W. McBride Human CYP1A1 gene: cosegregation of the enzyme inducibility phenotype and an RFLP Am. J. Hum. Genet. 48 1991 720 725
16. H.M. Lachman, D.F. Papolos, T. Saito, Y.M. Yu, C.L. Szumlanski and R.M. Weinshilboum Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders Pharmacogenetics 6 1996 243 250
17. S. Dawling, N. Roodi, R.L. Mernaugh, X. Wang and F.F. Parl Catechol-O-methyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms Cancer Res. 6 2001 6716 6722
18. C.S. Huang, H.D. Chern, K.J. Chang, C.W. Cheng, S.M. Hsu and C.Y. Shen Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility Cancer Res. 59 1999 4870 4875
19. E.I. Garner, E.E. Stokes, R.S. Berkowitz, S.C. Mok and D.W. Cramer Polymorphisms of the estrogen-metabolizing genes CYP17 and catechol-O- methyltransferase and risk of epithelial ovarian cancer Cancer Res. 62 2002 3058 3062
20. H.S. Feigelson, G.A. Coetzee, L.N. Kolonel, R.K. Ross and B.E. Henderson A polymorphism in the CYP17 gene increases the risk of breast cancer Cancer Res. 57 1997 1063 1065
21. C.A. Haiman, S.E. Hankinson, D. Spiegelman, G.A. Colditz, W.C. Willett, and F.E. Speizer The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer Cancer Res. 59 1999 1015 1020
22. A. Gsur, G. Bernhofer, S. Hinteregger, G. Haidinger, G. Schatzl, and S. Madersbacher A polymorphism in the CYP17 gene is associated with prostate cancer risk Int. J. Cancer 87 2000 434 437
23. V.N. Kristensen, E.K. Haraldsen, K.B. Andersson, P.E. Lonning, B. Erikstein, and R. Karesen CYP17 and breast cancer. The polymorphism in the 5′ flanking area of CYP17 does not influence binding to SP-1 Cancer Res. 59 1999 2825 2828
24. T. Habuchi, Z. Liqing, T. Suzuki, R. Sasaki, N. Tsuchiya, and H. Tachiki Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect Cancer Res. 60 2000 5710 5713
25. J.E. Goodman, J.A. Lavigne, J.G. Hengstler, B. Tanner, K.J. Helzlsouer and J.D. Yager Catechol-O-methyltransferase polymorphism is not associated with ovarian cancer risk Cancer Epidemiol. Biomarkers Prev. 9 2000 1373 1376
26. N.J. Walker, C.J. Portier, S.F. Lax, F.G. Crofts, Y. Li, and G.W. Lucier Characterization of the dose-response of CYP1B1, CYP1A1, and CYP1A2 in the liver of female Sprague-Dawley rats following chronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin Toxicol. Appl. Pharmacol. 154 1999 279 286
27. A.M. Tritscher, A.M. Seacat, J.D. Yager, J.D. Groopman, B.D. Miller, and D. Bell Increased oxidative DNA damage in livers of 2,3,7,8-tetrachlorodibenzo- p-dioxin treated intact but not ovariectomized rats Cancer Lett. 98 1996 219 225
28. J.R. Palmer, L. Rosenberg, D.W. Kaufman, M.E. Warshauer, P. Stolley and S. Shapiro Oral contraceptive use and liver cancer Am. J. Epidemiol. 130 1989 878 882
29. T. Ogawa, S. Higashi, Y. Kawarada and R. Mizumoto Role of reactive oxygen in synthetic estrogen induction of hepatocellular carcinomas in rats and preventive effect of vitamins Carcinogenesis 16 1995 831 836
30. H.L. Lin, T.Y. Liu, G.Y. Chau, W.Y. Lui and C.W. Chi Comparison of 2-methoxyestradiol, docetaxel, and paclitaxel-induced apoptosis in hepatoma cells and its correlation with reactive oxygen species Cancer 89 2000 983 994
31. G. Schumacher, S. Scheunert, A.K. Nuessler, A. Weber, A. Mueller, and K.P. Platz 2-Methoxyestradiol inhibits tumor growth and induces apoptosis in human hepatoma cells Proc. Am. Assoc. Cancer Res. 41 2000 772 773
32. M. Cushman, H.M. He, J.A. Katzenellenbogen, C.M. Lin and E. Hamel Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site J. Med. Chem. 38 1995 2041 2049
33. T. Mukhopadhyay and J.A. Roth Superinduction of wild-type p53 protein after 2-methoxyestradiol treatment of Ad5p53-transduced cells induces tumor cell apoptosis Oncogene 17 1998 241 246
34. H. Attalla, J.A. Westberg, L.C. Andersson, H. Adlercreutz and T.P. Makela 2-Methoxyestradiol-induced phosphorylation of Bcl-2: uncoupling from JNK/SAPK activation Biochem. Biophys. Res. Commun. 247 1998 616 619
35. T. Fotsis, Y. Zhang, M.S. Pepper, H. Adlercreutz, R. Montesano, and P.P. Nawroth The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth Nature 368 1994 237 239
36. W.Y. Lui, H.L. Lin, G.Y. Chau, T.Y. Liu and C.W. Chi Male predominance in hepatocellular carcinoma: new insight and a possible therapeutic alternative Med. Hypotheses 55 2000 348 350